Charles River Laboratories Other Non-Current Liabilities 2010-2025 | CRL

Charles River Laboratories other non-current liabilities for the quarter ending June 30, 2025 were $0.185B, a 17.51% decline year-over-year.

  • Charles River Laboratories other non-current liabilities for 2024 were $0.195B, a 12.54% decline from 2023.
  • Charles River Laboratories other non-current liabilities for 2023 were $0.223B, a 27.67% increase from 2022.
  • Charles River Laboratories other non-current liabilities for 2022 were $0.175B, a 28.02% decline from 2021.

Charles River Laboratories Other Non-Current Liabilities 2010-2025 | CRL

  • Charles River Laboratories other non-current liabilities for 2024 were $0.195B, a 12.54% decline from 2023.
  • Charles River Laboratories other non-current liabilities for 2023 were $0.223B, a 27.67% increase from 2022.
  • Charles River Laboratories other non-current liabilities for 2022 were $0.175B, a 28.02% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$147.4B
CVS Health (CVS)$92.8B
Elevance Health (ELV)$71.8B
Cencora (COR)$56.5B
DiDi Global (DIDIY)$27.5B
Labcorp Holdings (LH)$23.1B
Natera (NTRA)$23.1B
BioMerieux (BMXMF)$16.6B
EUROFINS SCIENT (ERFSF)$14.6B
ICON (ICLR)$14.4B
Medpace Holdings (MEDP)$13.4B
CochLear (CHEOY)$12.9B
Solventum (SOLV)$12.7B
Viatris (VTRS)$12.3B
Caris Life Sciences,�Inc (CAI)$10.8B
Revvity (RVTY)$10.5B
Avantor (AVTR)$9.2B
Sonic Healthcare (SKHHY)$7.7B
HealthEquity (HQY)$7.7B
Bausch + Lomb (BLCO)$5.2B
Sotera Health (SHC)$4.6B
BrightSpring Health Services (BTSG)$4.2B
Amplifon S.p.A (AMFPF)$3.9B
GeneDx Holdings (WGS)$3.7B
Alignment Healthcare (ALHC)$3.2B
Concentras Parent (CON)$3.1B
Surgery Partners (SGRY)$2.9B
Organon (OGN)$2.4B
Premier (PINC)$2.1B
KindlyMD (NAKA)$2B